Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2018
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2018
SUMMARY
According to the recently published report 'Nuclear Receptor ROR Gamma - Pipeline Review, H2 2018'; Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) pipeline Target constitutes close to 39 molecules. Out of which approximately 37 molecules are developed by companies and remaining by the universities/institutes.
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - RAR-related orphan receptor gamma (ROR?) is a protein encoded by the RORC gene. ROR? is member of the nuclear receptor family of transcription factors. It exist in two isoforms ROR? and ROR?t. ROR? is expressed in many tissues, including thymus, lung, liver, kidney, muscle, and brown fat. R OR?t, appears to be highly restricted to the thymus. ROR? isoform is involved in the regulation of circadian rhythms and ROR?t plays an important regulatory role in thymopoiesis and in inhibiting apoptosis.
The report 'Nuclear Receptor ROR Gamma - Pipeline Review, H2 2018' outlays comprehensive information on the Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 6, 21, 7 and 1 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Central Nervous System, Gastrointestinal, Oncology, Musculoskeletal Disorders, Respiratory, Dermatology and Metabolic Disorders which include indications Psoriasis, Rheumatoid Arthritis, Autoimmune Disorders, Inflammation, Multiple Sclerosis, Inflammatory Bowel Disease, Non-Alcoholic Steatohepatitis (NASH), Plaque Psoriasis (Psoriasis Vulgaris), Psoriatic Arthritis, Adenocarcinoma Of The Gastroesophageal Junction, Allergies, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, Asthma, Bladder Cancer, Breast Cancer, Chronic Obstructive Pulmonary Disease (COPD), Encephalomyelitis, Esophageal Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Idiopathic Pulmonary Fibrosis, Kidney Cancer (Renal Cell Cancer), Liver Fibrosis, Metastatic Transitional (Urothelial) Tract Cancer, Neuromyelitis Optica (Devic’s Syndrome), Non-Small Cell Lung Cancer, Ovarian Cancer, Skin Inflammation, Solid Tumor, Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Nuclear Receptor ROR Gamma - Pipeline Review, H2 2018'; Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) pipeline Target constitutes close to 39 molecules. Out of which approximately 37 molecules are developed by companies and remaining by the universities/institutes.
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - RAR-related orphan receptor gamma (ROR?) is a protein encoded by the RORC gene. ROR? is member of the nuclear receptor family of transcription factors. It exist in two isoforms ROR? and ROR?t. ROR? is expressed in many tissues, including thymus, lung, liver, kidney, muscle, and brown fat. R OR?t, appears to be highly restricted to the thymus. ROR? isoform is involved in the regulation of circadian rhythms and ROR?t plays an important regulatory role in thymopoiesis and in inhibiting apoptosis.
The report 'Nuclear Receptor ROR Gamma - Pipeline Review, H2 2018' outlays comprehensive information on the Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 6, 21, 7 and 1 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Central Nervous System, Gastrointestinal, Oncology, Musculoskeletal Disorders, Respiratory, Dermatology and Metabolic Disorders which include indications Psoriasis, Rheumatoid Arthritis, Autoimmune Disorders, Inflammation, Multiple Sclerosis, Inflammatory Bowel Disease, Non-Alcoholic Steatohepatitis (NASH), Plaque Psoriasis (Psoriasis Vulgaris), Psoriatic Arthritis, Adenocarcinoma Of The Gastroesophageal Junction, Allergies, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, Asthma, Bladder Cancer, Breast Cancer, Chronic Obstructive Pulmonary Disease (COPD), Encephalomyelitis, Esophageal Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Idiopathic Pulmonary Fibrosis, Kidney Cancer (Renal Cell Cancer), Liver Fibrosis, Metastatic Transitional (Urothelial) Tract Cancer, Neuromyelitis Optica (Devic’s Syndrome), Non-Small Cell Lung Cancer, Ovarian Cancer, Skin Inflammation, Solid Tumor, Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)
- The report reviews Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics and enlists all their major and minor projects
- The report assesses Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Overview
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Companies Involved in Therapeutics Development
AbbVie Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Beijing Hanmi Pharmaceutical Co Ltd
Biogen Inc
Boston Pharmaceuticals Inc
Brickell Biotech Inc
Bristol-Myers Squibb Co
Celgene Corp
Daiichi Sankyo Co Ltd
Escalier Biosciences BV
Genentech Inc
Genfit SA
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Johnson & Johnson
Lead Pharma Holding BV
LEO Pharma A/S
Lycera Corp
Maruho Co Ltd
Novartis AG
Nuevolution AB
Orphagen Pharmaceuticals Inc
Pfizer Inc
Phenex Pharmaceuticals AG
Reata Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Visionary Pharmaceuticals Inc
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Drug Profiles
A-213 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABBV-157 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-0284 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBI-6000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOS-172767 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CD-12681 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRC-39815 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2981278 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMU-366 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INV-17 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INV-71 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-3534 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JTE-451 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-0186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LYC-55716 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RTA-1701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Nuclear Receptor ROR Gamma for Autoimmune Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ROR-Gamma for Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ROR Gamma for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit RORC for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target ROR Gamma for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize ROR gamma for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize ROR-Gamma for Autoimmune Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize RORC for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ROR Gamma for Gastrointestinal and Immunology Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ROR-Gamma for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RORC for Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RORC for Autoimmune Disorders and Psoriasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis, Non-Alcoholic Steatohepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RORC for Psoriasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RORgamma for Rheumatoid Arthritis, Inflammatory Bowel Disease, Dermatology and Psoriatic Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ROR gamma-t for Autoimmune Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ROR Gamma-t for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-2211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TGFTX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMP-778 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Dormant Products
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Discontinued Products
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Product Development Milestones
Featured News & Press Releases
Jun 20, 2018: Reata Announces Initiation of a Phase 1 Trial of RTA 1701, a Selective, Oral Allosteric Inhibitor of ROR gamma t
Jun 01, 2018: Reata Selected to Present on its Early-Stage Program RTA 1701 at the BIO International Convention
May 30, 2018: Lycera to Present on First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 ASCO Annual Meeting
May 21, 2018: Karo Pharma Receives Milestone Payment for RORgamma Project From Pfizer
May 16, 2018: Lycera Announces Publication of Preclinical Immuno-Oncology Research, Demonstrating that Treatment with RORgamma Agonists Enhances CAR T-Cell Anti-Tumor Activity and Persistence, Resulting in Long-Lasting Anti-Tumor Memory T-Cells in an In Vivo Model
Apr 26, 2018: Nuevolution obtains new data in its internal RORt program supporting effect in human inflammatory bowel diseases
Apr 17, 2018: Lycera Presents Clinical Safety and Dose Selection Results for First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 AACR Annual Meeting
Apr 05, 2018: Lycera to Present Clinical Results and Supporting Preclinical Data for First-In-Class RORgamma Agonist LYC-55716 at the 2018 AACR Annual Meeting
Apr 03, 2018: Reata to Present Preclinical Data on RTA 1701, a Novel RORt Inverse Agonist, at Upcoming Immunology Conference
Mar 16, 2018: Reata to Present on its Autoimmune and Inflammatory Disorders Drug Candidate at the BIO Asia International Conference
Jan 04, 2018: Lycera Announces Initiation of Phase 1b Study of Novel Immuno-Oncology Candidate LYC-55716 in Combination with Pembrolizumab
Nov 21, 2017: Lead Pharma Achieves Third Milestone in Sanofi Collaboration for Development of Autoimmune Diseases Treatments
Nov 07, 2017: Lycera Presents Tumor Selection Rationale for Phase 2a Study at Society for Immunotherapy of Cancer’s (SITC) 2017 Annual Meeting for RORgamma Agonist, LYC-55716
Oct 19, 2017: Lycera Announces Advancement of Novel Immuno-Oncology Candidate LYC-55716 RORgamma Agonist into Phase 2a
Oct 04, 2017: Exelixis to Receive Milestone Payment from Bristol-Myers Squibb for Submission of Clinical Trial Authorization for RORC Inverse Agonist Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Overview
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Companies Involved in Therapeutics Development
AbbVie Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Beijing Hanmi Pharmaceutical Co Ltd
Biogen Inc
Boston Pharmaceuticals Inc
Brickell Biotech Inc
Bristol-Myers Squibb Co
Celgene Corp
Daiichi Sankyo Co Ltd
Escalier Biosciences BV
Genentech Inc
Genfit SA
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Johnson & Johnson
Lead Pharma Holding BV
LEO Pharma A/S
Lycera Corp
Maruho Co Ltd
Novartis AG
Nuevolution AB
Orphagen Pharmaceuticals Inc
Pfizer Inc
Phenex Pharmaceuticals AG
Reata Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Visionary Pharmaceuticals Inc
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Drug Profiles
A-213 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABBV-157 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-0284 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBI-6000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOS-172767 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CD-12681 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRC-39815 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2981278 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMU-366 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INV-17 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INV-71 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-3534 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JTE-451 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-0186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LYC-55716 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RTA-1701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Nuclear Receptor ROR Gamma for Autoimmune Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ROR-Gamma for Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ROR Gamma for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit RORC for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target ROR Gamma for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize ROR gamma for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize ROR-Gamma for Autoimmune Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize RORC for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ROR Gamma for Gastrointestinal and Immunology Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ROR-Gamma for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RORC for Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RORC for Autoimmune Disorders and Psoriasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis, Non-Alcoholic Steatohepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RORC for Psoriasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RORgamma for Rheumatoid Arthritis, Inflammatory Bowel Disease, Dermatology and Psoriatic Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ROR gamma-t for Autoimmune Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ROR Gamma-t for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-2211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TGFTX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMP-778 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Dormant Products
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Discontinued Products
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Product Development Milestones
Featured News & Press Releases
Jun 20, 2018: Reata Announces Initiation of a Phase 1 Trial of RTA 1701, a Selective, Oral Allosteric Inhibitor of ROR gamma t
Jun 01, 2018: Reata Selected to Present on its Early-Stage Program RTA 1701 at the BIO International Convention
May 30, 2018: Lycera to Present on First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 ASCO Annual Meeting
May 21, 2018: Karo Pharma Receives Milestone Payment for RORgamma Project From Pfizer
May 16, 2018: Lycera Announces Publication of Preclinical Immuno-Oncology Research, Demonstrating that Treatment with RORgamma Agonists Enhances CAR T-Cell Anti-Tumor Activity and Persistence, Resulting in Long-Lasting Anti-Tumor Memory T-Cells in an In Vivo Model
Apr 26, 2018: Nuevolution obtains new data in its internal RORt program supporting effect in human inflammatory bowel diseases
Apr 17, 2018: Lycera Presents Clinical Safety and Dose Selection Results for First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 AACR Annual Meeting
Apr 05, 2018: Lycera to Present Clinical Results and Supporting Preclinical Data for First-In-Class RORgamma Agonist LYC-55716 at the 2018 AACR Annual Meeting
Apr 03, 2018: Reata to Present Preclinical Data on RTA 1701, a Novel RORt Inverse Agonist, at Upcoming Immunology Conference
Mar 16, 2018: Reata to Present on its Autoimmune and Inflammatory Disorders Drug Candidate at the BIO Asia International Conference
Jan 04, 2018: Lycera Announces Initiation of Phase 1b Study of Novel Immuno-Oncology Candidate LYC-55716 in Combination with Pembrolizumab
Nov 21, 2017: Lead Pharma Achieves Third Milestone in Sanofi Collaboration for Development of Autoimmune Diseases Treatments
Nov 07, 2017: Lycera Presents Tumor Selection Rationale for Phase 2a Study at Society for Immunotherapy of Cancer’s (SITC) 2017 Annual Meeting for RORgamma Agonist, LYC-55716
Oct 19, 2017: Lycera Announces Advancement of Novel Immuno-Oncology Candidate LYC-55716 RORgamma Agonist into Phase 2a
Oct 04, 2017: Exelixis to Receive Milestone Payment from Bristol-Myers Squibb for Submission of Clinical Trial Authorization for RORC Inverse Agonist Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.1)
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AbbVie Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Aurigene Discovery Technologies Ltd, H2 2018
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2018
Pipeline by Biogen Inc, H2 2018
Pipeline by Boston Pharmaceuticals Inc, H2 2018
Pipeline by Brickell Biotech Inc, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Celgene Corp, H2 2018
Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Pipeline by Escalier Biosciences BV, H2 2018
Pipeline by Genentech Inc, H2 2018
Pipeline by Genfit SA, H2 2018
Pipeline by GlaxoSmithKline Plc, H2 2018
Pipeline by Glenmark Pharmaceuticals Ltd, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by Lead Pharma Holding BV, H2 2018
Pipeline by LEO Pharma A/S, H2 2018
Pipeline by Lycera Corp, H2 2018
Pipeline by Maruho Co Ltd, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Nuevolution AB, H2 2018
Pipeline by Orphagen Pharmaceuticals Inc, H2 2018
Pipeline by Pfizer Inc, H2 2018
Pipeline by Phenex Pharmaceuticals AG, H2 2018
Pipeline by Reata Pharmaceuticals Inc, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Pipeline by Visionary Pharmaceuticals Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.1)
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AbbVie Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Aurigene Discovery Technologies Ltd, H2 2018
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2018
Pipeline by Biogen Inc, H2 2018
Pipeline by Boston Pharmaceuticals Inc, H2 2018
Pipeline by Brickell Biotech Inc, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Celgene Corp, H2 2018
Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Pipeline by Escalier Biosciences BV, H2 2018
Pipeline by Genentech Inc, H2 2018
Pipeline by Genfit SA, H2 2018
Pipeline by GlaxoSmithKline Plc, H2 2018
Pipeline by Glenmark Pharmaceuticals Ltd, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by Lead Pharma Holding BV, H2 2018
Pipeline by LEO Pharma A/S, H2 2018
Pipeline by Lycera Corp, H2 2018
Pipeline by Maruho Co Ltd, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Nuevolution AB, H2 2018
Pipeline by Orphagen Pharmaceuticals Inc, H2 2018
Pipeline by Pfizer Inc, H2 2018
Pipeline by Phenex Pharmaceuticals AG, H2 2018
Pipeline by Reata Pharmaceuticals Inc, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Pipeline by Visionary Pharmaceuticals Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
AbbVie Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Beijing Hanmi Pharmaceutical Co Ltd
Biogen Inc
Boston Pharmaceuticals Inc
Brickell Biotech Inc
Bristol-Myers Squibb Co
Celgene Corp
Daiichi Sankyo Co Ltd
Escalier Biosciences BV
Genentech Inc
Genfit SA
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Johnson & Johnson
Lead Pharma Holding BV
LEO Pharma A/S
Lycera Corp
Maruho Co Ltd
Novartis AG
Nuevolution AB
Orphagen Pharmaceuticals Inc
Pfizer Inc
Phenex Pharmaceuticals AG
Reata Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Visionary Pharmaceuticals Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
AbbVie Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Beijing Hanmi Pharmaceutical Co Ltd
Biogen Inc
Boston Pharmaceuticals Inc
Brickell Biotech Inc
Bristol-Myers Squibb Co
Celgene Corp
Daiichi Sankyo Co Ltd
Escalier Biosciences BV
Genentech Inc
Genfit SA
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Johnson & Johnson
Lead Pharma Holding BV
LEO Pharma A/S
Lycera Corp
Maruho Co Ltd
Novartis AG
Nuevolution AB
Orphagen Pharmaceuticals Inc
Pfizer Inc
Phenex Pharmaceuticals AG
Reata Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Visionary Pharmaceuticals Inc
